Intra-Cellular Therapies Inc. (NASDAQ:ITCI) traded down 0.7% during trading on Friday . The company traded as low as $39.96 and last traded at $40.36, with a volume of 89,376 shares trading hands. The stock had previously closed at $40.63.

A number of equities research analysts have recently commented on the stock. Cowen and Company reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Intra-Cellular Therapies in a research note on Friday, August 5th. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research note on Tuesday, May 17th. Piper Jaffray Cos. assumed coverage on shares of Intra-Cellular Therapies in a research note on Wednesday, June 1st. They issued an “overweight” rating and a $57.00 price objective on the stock. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Intra-Cellular Therapies in a research note on Wednesday, June 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $70.78.

The company’s market cap is $1.75 billion. The stock has a 50-day moving average of $40.87 and a 200 day moving average of $35.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.08. During the same quarter in the previous year, the firm earned ($0.61) earnings per share. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.02 million. The company’s revenue for the quarter was up 283.3% compared to the same quarter last year. On average, equities research analysts predict that Intra-Cellular Therapies Inc. will post ($3.17) EPS for the current year.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.